Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pharmala Biotech Holdings Inc C.MDMA

Alternate Symbol(s):  MDXXF

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines: the manufacture of MDMA and MDXX class molecules for sale to clinical researchers in both the commercial and academic sphere, the research and development of novel MDXX class compounds which offer unique benefits above and beyond known substances, and the development of novel delivery mechanisms for MDMA and MDXX class compounds. Its research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. It works with laboratories across Canada to develop novel processes for the supply of LaNeo MDMA and other MDXX substances.


CSE:MDMA - Post by User

Pharmala Biotech Holdings Inc > Well done
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(157)
•••
Comment by Chefboy69on Oct 22, 2024 11:39am
20 Views
Post# 36276793

RE:RE:RE:RE:RE:Well done

RE:RE:RE:RE:RE:Well doneAgain you've proven yourself to me a total Noob and have no clue what you're talking about. I actually have traded this stock more than 15 or 20 times but I'm not about to lie about how the market works to line my pocket. I am what you call a straight shooter if you don't like that you can block me or mute me. But don't start trying to blow smoke up my rear end. I've been trading stocks for probably longer than you have been around on this planet
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities